Clinical Trials Logo
  1. Home
  2. Refractory Angina Pectoris
  3. NCT04121845

CoROnary SinuS Reducer implantatiOn for ischemiA reDuction — CrossRoad  

Refractory Angina Pectoris Clinical Trial

Official title:
The Influence of Coronary Sinus Reducer Implantation on Exertional Capacity, Extent of Myocardial Ischemia and hrECG Markers of Arrhythmogenicity in Patients With Refractory Angina Pectoris

Clinical Trial Summary

Patients with refractory angina pectoris have low quality of life and reduced exertional capacity. Studies have shown that the coronary sinus reducer (CSR) implantation improves the quality of life. However, to date there are no firm objective data on improvement of exertional capacity. Studies have shown a large influence of placebo effect after interventional procedures, which is even more pronounced than in medically treated patients. As angina pectoris presents entirely subjective perception of chest discomfort, its improvement may be influenced by this effect in up to 30 %. The investigators will study weather the CSR implantation improves aerobic exertional capacity in comparison to optimal medical therapy alone. Further, the investigators will explore the extent of myocardial reversible ischemia reduction and possible influence on hrECG markers of left ventricular arrhythmogenicity. 40 patients with refractory angina CCS class (Canadian cardiovascular society) II-IV and confirmed reversible ischemia will be included. Patients will be randomized into two groups. The first group will undergo CSR implantation procedure. The second group will present a sham control group with placebo procedure. At inclusion and after 6 months the investigators will perform cardiopulmonary exercise test (CPET), single photon emission tomography for detection of reversible ischemia (SPECT), high resolution ECG (hrECG), echocardiography and asses the subjective burden of angina according to CCS score and the quality of life according to the Seattle angina Questionnaire (SAQ).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04121845
Study type Interventional
Source University Medical Centre Ljubljana
Contact
Status Completed
Phase N/A
Start date January 1, 2019
Completion date June 30, 2022
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT03438500 - Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve N/A
Recruiting NCT01711099 - Efficacy of Extracorporeal Shockwave Myocardial Revascularization N/A
Active, not recruiting NCT03039751 - Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris Phase 2
Suspended NCT01567592 - Extracorporeal Shockwave Therapy for the Treatment of Chronic Angina Pectoris Phase 1
Recruiting NCT05711849 - Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina Phase 2
Active, not recruiting NCT01241968 - Extracorporeal Shock Wave Therapy for the Treatment of Ischemic Heart Disease Phase 2
Recruiting NCT02499250 - Effect of Daily Remote Ischemic Conditioning on the Life Quality of Refractory Angina Pectoris Patients N/A
Completed NCT01219218 - Extracorporeal Shockwave Therapy for the Treatment of Advanced Angina Pectoris Phase 1
Active, not recruiting NCT01567644 - Extracorporeal Shockwave Therapy for the Treatment of Refractory Chronic Angina Pectoris Phase 1
Completed NCT00662727 - Extracorporeal Shockwave Therapy for the Treatment of Refractory Angina Pectoris Phase 2
Active, not recruiting NCT05174572 - IMR Evaluation in Patients With Coronary Sinus Reducer Implantation (INROAD Study) N/A
Recruiting NCT04915157 - Efficacy of Spinal Cord Stimulation in Patients With Refractory Angina Pectoris N/A
Completed NCT01508910 - Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina Phase 3